Giovanni Staurenghi, Alcon Laboratories, Inc. (C), Alcon Laboratories, Inc. (R), Allergan (C), Bayer (C), Bayer (R), Boehringer Ingelheim (C), CenterVue (F), CenterVue (C), CenterVue (R), Heidelberg Engineering (C), Nidek, Inc. (F), Novartis (F), Novartis (C), Novartis (R), Ocular Instruments (P), Optos plc (F), Optos plc (C), Optovue (F), Quantel Medical (F), Quantel Medical (C), Quantel Medical (R), Roche (R), Roche/Genentech, Inc. (C), Zeiss (F), Zeiss (C);
Nancy Holekamp, Alimera Sciences, Inc. (F), Alimera Sciences, Inc. (C), Allergan (F), Allergan (C), Genentech, Inc. (F), Genentech, Inc. (C), Katalyst (I), Novartis (C), Ohr Pharmaceutical (F), Ophthotech, Corp. (F), Regeneron Pharmaceuticals, Inc. (C);
Jordi Mones, Alcon Laboratories, Inc. (F), Alcon Laboratories, Inc. (C), Alcon Laboratories, Inc. (R), Allergan (C), Bayer (F), Bayer (C), Bayer (R), Genentech, Inc. (C), Genentech, Inc. (R), Notal Vision (C), Novartis (C), Novartis (R), Ophthotech, Corp. (F), Ophthotech, Corp. (C), Ophthotech, Corp. (R), Roche (C), Roche (R);
Fan Tang, Genentech, Inc. (E);
Barbara Tong, Genentech, Inc. (E);
Ronald Cantrell, Genentech, Inc. (E);
Christopher Brittain, Genentech, Inc. (E);
Jason Ehrlich, Genentech, Inc. (E);
Hugh Lin, Genentech, Inc. (E);
Charles Wykoff, Apellis Pharmaceuticals (F), Genentech, Inc. (F), Genentech, Inc. (C), Ophthotech, Corp. (F)